Breaking News

Financial Report: AbbVie

April 26, 2013

Humira sales up 16% in first reporting quarter

1Q Revenues: $4.3 billion (+4%)
1Q Earnings: $968 million (+10%)
Comments: Growth was driven by Humira sales in the U.S. and internationally, up 16% to $2.2 billion. Synagis sales were $345 million, down 1%. AndroGel sales were up 3% to $240 million. TriCor/Trilipix sales were down 50% to $128 million due to the loss of exclusivity. Lupron sales were down 9% to $181 million.
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors